Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 GenprexEnlivex TherapeuticsAbeona TherapeuticsAptinyxNeuBase Therapeutics
SymbolNASDAQ:GNPXNASDAQ:ENLVNASDAQ:ABEONASDAQ:APTXNASDAQ:NBSE
Price Information
Current Price$3.84$10.14$1.61$2.77$5.76
52 Week RangeBuyBuyBuyBuyBuy
MarketRank™
Overall Score1.21.41.61.41.3
Analysis Score3.53.53.43.43.5
Community Score2.43.43.02.73.0
Dividend Score0.00.00.00.00.0
Ownership Score0.00.00.80.80.0
Earnings & Valuation Score0.00.00.60.00.0
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$6.00$33.00$5.17$11.67$17.33
% Upside from Price Target56.25% upside225.44% upside220.91% upside321.18% upside200.93% upside
Trade Information
Market Cap$167.05 million$160.59 million$150.54 million$182.16 million$139.08 million
Beta-0.571.141.691.470.41
Average Volume1,444,666400,7163,684,309535,219299,463
Sales & Book Value
Annual RevenueN/AN/A$3 million$3.67 millionN/A
Price / SalesN/AN/A53.1550.55N/A
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$0.15 per share$1.09 per share$2.13 per share$2.31 per share$1.35 per share
Price / BookN/AN/A0.761.20N/A
Profitability
Net Income$-10,650,000.00$-9,380,000.00$-76,280,000.00$-57,410,000.00$-17,390,000.00
EPS($0.67)($1.11)($1.51)($1.71)($0.89)
Trailing P/E RatioN/AN/AN/AN/AN/A
Forward P/E RatioN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/AN/A-2,108.05%N/A
Return on Equity (ROE)-81.49%-34.60%-37.97%-46.43%-90.43%
Return on Assets (ROA)-79.54%-28.47%-28.76%-44.60%-77.20%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/A0.02%N/AN/AN/A
Current Ratio60.40%7.23%2.70%26.50%10.42%
Quick Ratio58.58%7.23%2.70%26.50%10.42%
Ownership Information
Institutional Ownership Percentage12.50%2.39%36.47%43.89%28.98%
Insider Ownership Percentage13.05%N/A19.10%8.58%24.00%
Miscellaneous
Employees836N/A4315
Shares Outstanding43.28 million15.76 million99.04 million66.97 million23.18 million
Next Earnings Date5/13/2021 (Estimated)5/17/2021 (Estimated)5/5/2021 (Estimated)5/13/2021 (Estimated)5/13/2021 (Estimated)
OptionableNot OptionableNot OptionableOptionableNot OptionableNot Optionable
SourceHeadline
NeuBase Therapeutics, Inc. (NASDAQ:NBSE) Expected to Post Earnings of -$0.23 Per ShareNeuBase Therapeutics, Inc. (NASDAQ:NBSE) Expected to Post Earnings of -$0.23 Per Share
americanbankingnews.com - April 21 at 4:24 PM
12-month price target for NeuBase Therapeutics, Inc. (NASDAQ:NBSE) now sits at $1812-month price target for NeuBase Therapeutics, Inc. (NASDAQ:NBSE) now sits at $18
marketingsentinel.com - April 17 at 3:12 PM
Coya Therapeutics™ Announces the Appointment of Hideki Garren, M.D., Ph.D., and Dov Goldstein, M.D., to Its Board of DirectorsCoya Therapeutics™ Announces the Appointment of Hideki Garren, M.D., Ph.D., and Dov Goldstein, M.D., to Its Board of Directors
finance.yahoo.com - April 14 at 9:04 AM
NeuBase Therapeutics to Host a Virtual R&D Day on June 8th to Provide Updates on the Drug Development Pipeline Targeting Genetic DiseasesNeuBase Therapeutics to Host a Virtual R&D Day on June 8th to Provide Updates on the Drug Development Pipeline Targeting Genetic Diseases
finance.yahoo.com - April 8 at 9:28 AM
Zacks: Analysts Expect NeuBase Therapeutics, Inc. (NASDAQ:NBSE) Will Announce Earnings of -$0.23 Per ShareZacks: Analysts Expect NeuBase Therapeutics, Inc. (NASDAQ:NBSE) Will Announce Earnings of -$0.23 Per Share
americanbankingnews.com - April 4 at 8:42 AM
Heres What NeuBase Therapeutics, Inc.s (NASDAQ:NBSE) Shareholder Ownership Structure Looks LikeHere's What NeuBase Therapeutics, Inc.'s (NASDAQ:NBSE) Shareholder Ownership Structure Looks Like
finance.yahoo.com - March 19 at 12:04 PM
NeuBase Therapeutics to Present at the 2021 Muscular Dystrophy Association Virtual Clinical ...NeuBase Therapeutics to Present at the 2021 Muscular Dystrophy Association Virtual Clinical ...
apnews.com - March 17 at 10:05 AM
NeuBase Therapeutics to Present at the 2021 Muscular Dystrophy Association Virtual Clinical & Scientific ConferenceNeuBase Therapeutics to Present at the 2021 Muscular Dystrophy Association Virtual Clinical & Scientific Conference
finance.yahoo.com - March 16 at 8:19 AM
NeuBase Therapeutics to Present at Upcoming Investor Conferences in March 2021 Nasdaq: NBSENeuBase Therapeutics to Present at Upcoming Investor Conferences in March 2021 Nasdaq: NBSE
compsmag.com - March 9 at 6:13 PM
NeuBase Therapeutics to Present at Upcoming Investor Conferences in March 2021NeuBase Therapeutics to Present at Upcoming Investor Conferences in March 2021
finance.yahoo.com - March 9 at 8:12 AM
NeuBase Therapeutics Inc.NeuBase Therapeutics Inc.
barrons.com - March 5 at 1:27 PM
BRIEF—NeuBase buys gene modulating technology from Vera TherapeuticsBRIEF—NeuBase buys gene modulating technology from Vera Therapeutics
thepharmaletter.com - February 12 at 7:40 PM
NeuBase: Fiscal 1Q Earnings Snapshot | Raleigh News & ObserverNeuBase: Fiscal 1Q Earnings Snapshot | Raleigh News & Observer
newsobserver.com - February 11 at 7:39 PM
NeuBase Therapeutics Reports Financial Results for the First Quarter of Fiscal Year 2021NeuBase Therapeutics Reports Financial Results for the First Quarter of Fiscal Year 2021
finance.yahoo.com - February 11 at 7:39 PM
NBSE Feb 2021 17.500 callNBSE Feb 2021 17.500 call
uk.finance.yahoo.com - February 9 at 5:38 PM
NeuBase Therapeutics Announces Acquisition of Gene Modulating Technology from Vera TherapeuticsNeuBase Therapeutics Announces Acquisition of Gene Modulating Technology from Vera Therapeutics
markets.businessinsider.com - January 28 at 8:58 AM
NBSE Feb 2021 12.500 putNBSE Feb 2021 12.500 put
uk.finance.yahoo.com - January 27 at 5:16 PM
NBSE May 2021 2.500 callNBSE May 2021 2.500 call
uk.finance.yahoo.com - January 26 at 10:47 PM
NBSE Aug 2021 7.500 callNBSE Aug 2021 7.500 call
uk.finance.yahoo.com - January 26 at 5:47 PM
Is Neubase Therapeutics (NBSE) Stock a Buy For 2021?Is Neubase Therapeutics (NBSE) Stock a Buy For 2021?
finance.yahoo.com - January 22 at 12:49 AM
NeuBase Therapeutics to Present at the H.C. Wainwright Virtual BioConnect ConferenceNeuBase Therapeutics to Present at the H.C. Wainwright Virtual BioConnect Conference
finance.yahoo.com - January 11 at 8:33 AM
NeuBase: Fiscal 4Q Earnings Snapshot | Raleigh News & ObserverNeuBase: Fiscal 4Q Earnings Snapshot | Raleigh News & Observer
newsobserver.com - December 23 at 6:55 PM
NeuBase: Fiscal 4Q Earnings Snapshot | Charlotte ObserverNeuBase: Fiscal 4Q Earnings Snapshot | Charlotte Observer
charlotteobserver.com - December 23 at 6:55 PM
NeuBase: Fiscal 4Q Earnings SnapshotNeuBase: Fiscal 4Q Earnings Snapshot
sfgate.com - December 23 at 6:55 PM
NeuBase Therapeutics Reports Business Update and Financial Results for Fiscal Year 2020NeuBase Therapeutics Reports Business Update and Financial Results for Fiscal Year 2020
finance.yahoo.com - December 23 at 6:55 PM
DateCompanyBrokerageAction
1/26/2021GenprexNational SecuritiesInitiated Coverage
5/26/2020GenprexNoble FinancialReiterated Rating
4/22/2020GenprexAlliance Global PartnersInitiated Coverage
4/1/2019GenprexMaxim GroupDowngrade
3/2/2021Enlivex TherapeuticsHC WainwrightBoost Price Target
3/29/2021Abeona TherapeuticsSVB LeerinkReiterated Rating
11/11/2020Abeona TherapeuticsB. RileyReiterated Rating
11/10/2020Abeona TherapeuticsCantor FitzgeraldUpgrade
5/8/2020Abeona TherapeuticsRoyal Bank of CanadaLower Price Target
5/7/2020Abeona TherapeuticsMizuhoReiterated Rating
1/29/2021AptinyxJPMorgan Chase & Co.Downgrade
10/27/2020AptinyxPiper SandlerInitiated Coverage
10/21/2020AptinyxCowenReiterated Rating
10/1/2020AptinyxWilliam BlairReiterated Rating
8/14/2020AptinyxBMO Capital MarketsReiterated Rating
7/1/2020AptinyxSunTrust BanksInitiated Coverage
9/12/2019AptinyxWedbushInitiated Coverage
3/18/2021NeuBase TherapeuticsOppenheimerReiterated Rating
8/14/2020NeuBase TherapeuticsChardan CapitalReiterated Rating
2/6/2020NeuBase TherapeuticsGuggenheimInitiated Coverage
9/24/2019NeuBase TherapeuticsBTIG ResearchInitiated Coverage
(Data available from 4/22/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.